Te Ahumairangi Investment Management Ltd Has $6.31 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Te Ahumairangi Investment Management Ltd lowered its position in DaVita Inc. (NYSE:DVA) by 12.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,170 shares of the company’s stock after selling 5,967 shares during the quarter. DaVita accounts for approximately 1.3% of Te Ahumairangi Investment Management Ltd’s investment portfolio, making the stock its 23rd largest position. Te Ahumairangi Investment Management Ltd owned approximately 0.05% of DaVita worth $6,307,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in shares of DaVita by 134.6% during the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock valued at $8,885,000 after acquiring an additional 31,502 shares during the last quarter. FMR LLC raised its position in DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in DaVita by 201.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company’s stock worth $11,159,000 after buying an additional 49,885 shares during the period. Neo Ivy Capital Management bought a new stake in shares of DaVita in the 3rd quarter valued at about $726,000. Finally, Hussman Strategic Advisors Inc. increased its stake in shares of DaVita by 200.0% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company’s stock valued at $3,769,000 after buying an additional 16,800 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 0.7 %

DaVita stock opened at $151.82 on Wednesday. The company has a market capitalization of $12.15 billion, a PE ratio of 14.14, a PEG ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 12-month low of $125.64 and a 12-month high of $179.60. The firm’s fifty day moving average is $156.77 and its 200 day moving average is $157.44. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Cowen reissued a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, StockNews.com cut shares of DaVita from a “buy” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.